Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- INSTYTUTUMINSTYTUTUM Clinical Study Shows a Three-Year Reduction in Calculated Skin Biological Age in 84 DaysSwiss longevity skincare brand reveals new clinical data supporting a new approach to skin health, biological aging and skinspan — INSTYTUTUM, the Swiss longevity skincare brand founded by longevity scientist and biotech innovator Dr. Natalia Bobok,...
- Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)Company announcement No. 50 / 2026
- Powerful NeOnc Brain Cancer Pipeline AdvancesNeOnc (NASDAQ: NTHI) is scheduled to meet with the FDA for an in-person End-of-Phase 1 Type B meeting covering its experimental brain-cancer drug NEO212.
- Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer StudyOncolytics announced continued clinical and operational progress for the REO 033 program evaluating pelareorep in second-line RAS-mutant mCRC.
- Children's Hospital of PhiladelphiaChildren's Hospital of Philadelphia Celebrates First Anniversary of Pediatric Health Chat Initiative– CHOP Experts Counter Pediatric Health Misinformation with Evidence-Based Guidance for Families — — This month, Children's Hospital of Philadelphia (CHOP) marks the first anniversary of its Pediatric Health Chat initiative, a pioneering online...
- AINGENSMedical Affairs Teams Pay a "Tool-Switching Tax" for Fragmented AICompanies: GartnerAs AI tools spread across medical affairs workflows, AINGENS CEO Ome Ogbru warns that disconnected systems can increase cognitive load, weaken traceability, and make regulated scientific work harder to govern, audit, and defend. COLUMBIA, Md., Sept. 28, 2026 -- By 2028, the...
- Clearity HealthAustin-Based Clearity Health Launches Physician-Led Medical Bill Negotiation Service With Fees Capped at $1,000Patients pay nothing upfront, and only pay if Clearity saves them money — Clearity Health, founded by physicians Dr. Shankar Arul and Dr. Arthur Abello, today announced the launch of its medical bill negotiation service. Clearity's physician-led...
- Pediatric Clinical Trials Market Projected to Reach USD 35.64 Billion by 2035, Growing at a CAGR of 4.30% - SNS InsiderU.S. Pediatric Clinical Trials Market to Reach USD 11.82 Billion and Europe USD 10.13 Billion by 2035 as Regulatory Incentives, Pediatric Drug Pipelines, and Decentralized Trial Models Accelerate Research Activity.
- NewcelX Ltd.NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 DiabetesFollowing successful FDA Pre-IND meeting, NewcelX advances IND-enabling activities for NCEL-101
- GuideAI Health Corp.GuideAI Health Corp. and vRad Renew Data Exclusivity Agreement to Develop AI Models for the Detection and Characterization of Multiple Vascular DiseasesCompany holds exclusive access to imaging data from 2,100+ U.S. hospitals through its ongoing data partnership with vRad, the largest teleradiology provider in the United States
- ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric CancerAchieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2-positive disease
- 4D Molecular Therapeutics, Inc. 4D-150 is advancing into Phase 3 development for4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular edema (DME). The Company also reported 2-year data from the SPECTRA clinical trial.